Floatz logo

Lorlatinib

High Grade Glioma

Nationwide Children's HospitalSmall moleculeEarly Phase 1Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
81/ 100

Competitive context

108 Active assets in the High Grade Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Kailin Yang, MD, PhD
Phase 2BB
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
Valproic Acid
Virginia Commonwealth University
Phase 2BB
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE
Oblato, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Lorlatinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
neoplastic meningitisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →